EBV-specific T cells as therapy for relapsed - refractory EBV-positive lymphomas

EBV 特异性 T 细胞治疗复发难治性 EBV 阳性淋巴瘤

• 批准号: nhmrc : 552469
• 负责人: Prof David Ritchie
• 金额: $ 21.63万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/ebv-specific-t-positive-lymphomas/95502
• 关键词: EBV; specific; cells; therapy; relapsed

The presence of Epstein-Barr virus (EBV) withiin EBV-positive malignant lymphoma cases provides a potential target for adoptive immunotherapy. Previous studies have established that adoptive immunotherapy for certain subtypes of lymphoma with EBV-specific killer T cells can lead to remission of disease. The objective of this study is to examine whether a similar strategy but using an enhanced methodology can be applied for the treatment of a range of relapsed-refractory EBV-positive lymphomas.

EBV 阳性恶性淋巴瘤病例中存在 Epstein-Barr 病毒 (EBV)，这为过继性免疫治疗提供了潜在的靶标。先前的研究已经证实，使用 EBV 特异性杀伤 T 细胞对某些淋巴瘤亚型进行过继免疫治疗可以缓解疾病。本研究的目的是检查是否可以采用类似的策略但使用增强的方法来治疗一系列复发难治性 EBV 阳性淋巴瘤。